• CD28 targeting
  • How it works

CD28 targeting

Safe and selective activation of CD28 on T cells

Despite advances in cancer immunotherapy, resistance and relapse remain common. Bispecific antibodies (bsAbs) targeting CD28 enhance T cell activation mediated through the T cell receptor (TCR), known as “signal 1”. Unlike CD28 monoclonal agonistic antibodies, bsAbs need tumor-associated antigen (TAA) binding to activate CD28. Thus, tumor-targeted CD28 bsAbs only prompt T cell activation within the tumor microenvironment, by connecting T cells to TAAs on cancer cells and unleashing their full cytotoxic potential with "signal 2".

In the case of NI-3201 targeting CD28/PD-L1, the CD28 co-stimulation is dependent on the engagement and blockade of PD-L1, as shown in the video below

Do you want to know more about CD28 costimulation?
Interested by this approach for your own projects? Partner with us.

New publication in ImmunoTherapy of Cancer

Selective activation of interleukin-2/interleukin-15 receptor signaling in tumor microenvironment using paired bispecific antibodies

Read more

LinkedIn